Skip to main content
SpringerLink
Log in

Early Non-small Cell Lung Cancer: The Place of Radical Non-SABR Radiation Therapy

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 348 Accesses

Abstract

The evidence for radiotherapy as a potentially curative treatment for early lung cancer has gradually accumulated over the past 50 years with our conventional gold standard of 60 Gy in 30 fractions over 6 weeks established in the 1980s. A multimodality approach is now standard for the management of most presentations of lung cancer with concurrent chemoradiotherapy/immunotherapy combinations being standard of care for stage III disease. In parallel, technological developments enabled us to establish stereotactic ablative body radiotherapy (SABR) as the standard of care for inoperable stage I disease.

Unfortunately, a significant proportion of patients presenting to our day-to-day practice will not be best served by the gold standard treatments of SABR or the concurrent chemoradiotherapy/immunotherapy combinations. For these patients, it is the use of non-SABR radiation schedules that offers potentially curative treatment as a single modality or combined with chemotherapy. Awareness and interest in an accelerated approach have been increased by the COVID-19 pandemic. This chapter reviews the evidence for non-SABR radiation schedules as they continue to have an important role in the management of early-stage NSCLC in combination with all other aspects of care in the control of symptoms and maintenance of quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350. https://doi.org/10.1056/NEJMoa1809697

    Article  Google Scholar 

  • Antonio M, Saldana J, Linares J, Ruffinelli JC, Palmero R, Navarro A et al (2018) Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer. Br J Cancer 118:639–647. https://doi.org/10.1038/bjc.2017.455

    Article  Google Scholar 

  • Arriagada R, Le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard JY et al (1991) Effect of chemotherapy on locally advanced non-small lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 20:1183–1190. https://doi.org/10.1016/0360-3016(91)90226-t

    Article  Google Scholar 

  • Arriagada R, Komaki R, Cox JD (2004) Radiation dose escalation in non-small cell carcinoma of the lung. Semin Radiat Oncol 14:287–291

    Article  Google Scholar 

  • Aupérin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190

    Article  Google Scholar 

  • Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G et al (1999) A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 52:129–136. https://doi.org/10.1016/s0167-8140(99)00093-6

    Article  Google Scholar 

  • Ball D, Mai GT, Vinod D et al (2019) Stereotactic ablative body radiotherapy versus standard radiotherapy in inoperable stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol 20:494–503

    Article  Google Scholar 

  • Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al, On behalf of the CHARTWEL-Bronchus Group (2011) Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated vs conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 100:76–85. https://doi.org/10.1016/j.radonc.2011.06.031

  • Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M et al (2005) Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23(16):3760–3767. https://doi.org/10.1200/JCO.2005.09.108

    Article  Google Scholar 

  • Belderbos JSA, De Jaeger K, Heemsbergen WD, Seppenwoolde Y, Bass P, Boersma LJ et al (2006) Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66:126–134. https://doi.org/10.1016/j.ijrobp.2006.04.034

    Article  Google Scholar 

  • Bissonnette JP, Purdie TG, Higgins JA, Li W, Bezjak A (2009) Cone-beam computed tomographic image guidance for lung cancer radiation therapy. Int J Radiat Oncol Biol Phys 73:927–934

    Article  Google Scholar 

  • Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE et al (2020) Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol 38(7):706–714. https://doi.org/10.1200/JCO.19.01162

    Article  Google Scholar 

  • Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier J-P, Varela G et al (2009) ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 34:17–41

    Article  Google Scholar 

  • Burt PA, Hancock BM, Stout R (1989) Radical radiotherapy for carcinoma of the bronchus: an equal alternative to radical surgery? Clin Oncol 1:86–90. https://doi.org/10.1016/s0936-6555(89)80041-x

    Article  Google Scholar 

  • Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA et al (2013) Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 31(34):4343–4348

    Article  Google Scholar 

  • Chan C, Lang S, Rowbottom C, Guckenberger M, Faivre-Finn C, IASLC Advanced Radiation Technology Committee (2014) Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol 9(11):1598–1608. https://doi.org/10.1097/JTO.0000000000000346

    Article  Google Scholar 

  • Charloux A (2011) Fitness for radical treatment of lung cancer patients. Breathe 7:221–228

    Article  Google Scholar 

  • Cheng M, Jolly S, Quarshie WO, Kapadia N, Vigneau FD, Kong FS (2019) Modern radiation further improves survival in non-small cell lung cancer: an analysis of 288,670 patients. J Cancer 10(1):168–177

    Article  Google Scholar 

  • Cho WK, Noh JM, Ahn YC, Oh D, Pyo H (2016) Radiation therapy alone in cT1-3N0 non-small cell lung cancer patients who are unfit for surgical resection or stereotactic radiation therapy: comparison of risk-adaptive dose schedules. Cancer Res Treat 48:1187–1195. https://doi.org/10.4143/crt.2015.391

    Article  Google Scholar 

  • Cooke S, De Ruysscher D, Reymen B, Lambrecht M, Fredberg PG, Faivre-Finn C et al (2021) Local, regional and pulmonary failures in the randomised PET-boost trial for NSCLC. J Thorac Oncol 16(3 Suppl):113, Abstract OA02.05

    Google Scholar 

  • Cooper JD, Pearson FD, Todd TR, Patterson GA, Ginsberg RJ, Basiuk J et al (1985) Radiotherapy alone for patients with operable carcinoma of the lung. Chest 87:289–292. https://doi.org/10.1378/chest.87.3.289

    Article  Google Scholar 

  • Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF et al (1990) A randomized phase II/III trial of hyper-fractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83–11. J Clin Oncol 8:1543–1555. https://doi.org/10.1200/JCO.1990.8.9.1543

    Article  Google Scholar 

  • de Koning HJ, van der Aalst CM, de Jong PA, Scholten E, Nackaerts K, Heuvelmans MA et al (2020) Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382:503–513. https://doi.org/10.1056/NEJMoa1911793

    Article  Google Scholar 

  • Dieleman EMT, Uitterhoeve ALJ, van Hoek MW, van Os RM, Wiersma J, Koolen MGJ et al (2018) Concurrent daily cisplatin and high-dose radiation therapy in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 102(3):543–551. https://doi.org/10.1016/j.ijrobp.2018.07.188

    Article  Google Scholar 

  • Din OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF et al (2013) Accelerated hypo-fractionated radiotherapy for non-small cell lung cancer: results from 4 UK centres. Radiother Oncol 109(1):8–12

    Article  Google Scholar 

  • Dosoretz DE, Katin MJ, Blitzer PH, Rubenstein JH, Salenis S, Rashid M et al (1992) Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 24:3–9. https://doi.org/10.1016/0360-3016(92)91013-D

    Article  Google Scholar 

  • Driessen EJM, Bootsma GP, Hendriks LEL, van den Berkmortel FM, Bogaarts BA, van Loon JGM et al (2016) Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. Radiother Oncol 121:26–31

    Article  Google Scholar 

  • Du Ruysscher D, Wanders R, Van Haren E, Minken A, Bentzen SM, Lambin P et al (2007) Hi-CHART: a phase I/II study on the feasibility of high-dose continuous hyper-fractionated accelerated radiotherapy in patients with in-operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 71:132–138. https://doi.org/10.1016/j.ijrobp.2007.09.048

    Article  Google Scholar 

  • Faivre-Finn C, Fenwick JD, Franks KN, Harrow S, Hatton MQF, Hiley C et al (2020) Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic. Clin Oncol 32:481–489. https://doi.org/10.1016/j.clon.2020.05.001

    Article  Google Scholar 

  • Fenwick JD, Nahum AE, Malik ZI, Eswar CV, Hatton MQ, Laurence VM et al (2009) Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. Clin Oncol 21:343–360. https://doi.org/10.1016/j.clon.2008.12.011

    Article  Google Scholar 

  • Fenwick JD, Landau DB, Baker AT, Bates AT, Eswar C, Garcia-Alonso A et al (2020) Long-term results from the IDEAL-CRT phase 1/2 trial of isotoxically dose-escalated radiation therapy and concurrent chemotherapy for stage II/III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 106(4):733–742

    Article  Google Scholar 

  • Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, Eisen T et al (2016) UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 71:161–170

    Article  Google Scholar 

  • Fowler JF, Chappell R (2000) Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 46:516–517

    Article  Google Scholar 

  • Gauden S, Ramsay J, Tripciony L (1995) The curative treatment by radiotherapy alone of stage I non-small cell lung cancer. Chest 108:1278–1282. https://doi.org/10.1378/chest.108.5.1278

    Article  Google Scholar 

  • Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51

    Article  Google Scholar 

  • Graham PH, Gebski VJ, Stat M, Langlands AO (1995) Radical radiotherapy for early non-small cell lung cancer. Int J Radiat Oncol Biol Phys 31:261–266. https://doi.org/10.1016/0360-3016(94)E0137-9

    Article  Google Scholar 

  • Haffty BG, Goldberg NB, Gerstley J, Fisher DB, Peschel RD (1988) Results of radical radiotherapy in clinical stage I technically operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 15:69–73. https://doi.org/10.1016/0360-3016(88)90348-3

    Article  Google Scholar 

  • Hanna NH, Neubauer M, Ansari R et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26(35):5755–5760

    Article  Google Scholar 

  • Haslett K, Ashcroft L, Bayman N, Franks K, Groom N, Hanna G et al (2020) Isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2020.11.040

  • Hatton M, Lyn E, Nankivell M, Stephens R, Pugh C, Navani N et al (2011) Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART): the MRC INCH randomised trial. Int J Radiat Oncol Biol Phys 81:712–718

    Article  Google Scholar 

  • Hatton M, Hill R, Fenwick J, Morgan S, Wilson P, Atherton P et al (2016) Continuous hyperfractionated accelerated radiotherapy – escalated dose (CHART-ED): a phase I study. Radiother Oncol 118:471–477

    Article  Google Scholar 

  • Iocolano M, Wild AT, Hannum M, Zhang Z, Simone CB, Gelblum D et al (2020) Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy. Acta Oncol 59(2):164–170. https://doi.org/10.1080/0284186X.2019.1675907

    Article  Google Scholar 

  • Iyengar P, Westover KD, Court LE, Patel MK, Shivnani AT, Saunders MW et al (2016) A phase III randomized study of image guided conventional (60 Gy/30 fx) versus accelerated, hypofractionated (60 Gy/15 fx) radiation for poor performance status stage II and III NSCLC patients—an interim analysis. Int J Radiat Oncol Biol Phys 96:E451. https://doi.org/10.1016/j.ijrobp.2016.06.1763

    Article  Google Scholar 

  • Jeremic B, Milicic B (2008) From conventionally fractionated radiation therapy to hyper-fractionated radiation therapy alone and with concurrent chemotherapy in patients with early stage non-small cell lung cancer. Cancer 112:876–884

    Article  Google Scholar 

  • Jeremić B, Dubinsky P, Milisavljević S, Kiladze I (2021) Combined radiation therapy and chemotherapy as an exclusive treatment option in locally advanced inoperable non-small cell lung cancer. Medical Radiology. https://doi.org/10.1007/174_2021_277

  • Kaskowitz L, Graham MV, Emami B, Halverson KJ, Rush C (1993) Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 27:517–523. https://doi.org/10.1016/0360-3016(93)90374-5

    Article  Google Scholar 

  • Katz HR, Alberts RW (1983) A comparison of high dose continuous and split course irradiation in non-oat cell carcinoma of the lung. Am J Clin Oncol 6(4):445–457. https://doi.org/10.1097/00000421-198308000-00010

    Article  Google Scholar 

  • Knight SB, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C (2017) Progress and prospects of early detection in lung cancer. Open Biol 7(9):170070. https://doi.org/10.1098/rsob.170070

    Article  Google Scholar 

  • Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Gregoire V et al (2015) PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol 116:27–34

    Article  Google Scholar 

  • Kong FM, Ten Haken RK, Schipper MJ et al (2005) High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63:324–333

    Article  Google Scholar 

  • Kong F, Hu C, Machtay M, Matuszak M, Xiao Y, Ten Haken R et al (2021) Randomized phase II trial (RTOG1106) on mid treatment PET/CT guided adaptive radiotherapy in locally advanced non-small cell lung cancer. J Thorac Oncol 16(3 Suppl):112, Abstract OA02.04

    Google Scholar 

  • Krol AD, Aussems P, Noordijk EM, Hermans J, Leer JW et al (1996) Local irradiation alone for peripheral stage I lung cancer: could we omit local nodal irradiation? Int J Radiat Oncol Biol Phys 34:297–302. https://doi.org/10.1016/0360-3016(95)00227-8

    Article  Google Scholar 

  • Lester JF, Courtier N, Eswar C, Mohammed N, Fenwick J, Griffiths G et al (2018) Initial results of the phase Ib/II, I-START trial - isotoxic accelerated radiotherapy for the treatment of stage II–IIIB NSCLC. J Clin Oncol. https://doi.org/10.1200/JCO.2018.36.15_suppl.e20551

  • Maciejewski B, Withers HR, Taylor JMG et al (1989) Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose–response and repopulation. Int J Radiat Oncol Biol Phys 16:831–843

    Article  Google Scholar 

  • Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M et al (2012) Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 30(22):2788–2797. https://doi.org/10.1200/JCO.2012.41.6677

    Article  Google Scholar 

  • Morita K, Fuwa N, Suzuki Y, Nishio M, Sakai K, Tamaki Y et al (1997) Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 42:31–36. https://doi.org/10.1016/S0167-8140(96)01828-2

    Article  Google Scholar 

  • Noordijk EM, Van Poest Clement E, Hermans J, Wever AMJ, Leer JWH (1988) Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 13:83–89. https://doi.org/10.1016/0167-8140(88)90029-1

    Article  Google Scholar 

  • NSCLC Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899–909

    Article  Google Scholar 

  • Nyman J, Hallqvist A, Lund J, Brustugun O, Bergman B et al (2016) SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 121:1–8

    Article  Google Scholar 

  • Peeters ST, Dooms C, Van Baardwijk A, Dingemans AMC, Martinussen H, Vansteenkiste J et al (2016) Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: how to use E(B)US-NA information in addition to PET-CT for delineation? Radiother Oncol 120:273–278

    Article  Google Scholar 

  • Perez CA, Stanley K, Grundy G et al (1982) Impact of irradiation technique and tumour extent in tumour control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 50:1091–1099

    Article  Google Scholar 

  • Robinson SD, Tahir BA, Absalom KAR, Lankathilake A, Das T, Lee C et al (2019) Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): a 5-year retrospective review of two dose fractionation schedules. Radiother Oncol 143:37–43. https://doi.org/10.1016/j.radonc.2019.08.025

    Article  Google Scholar 

  • Roswit B, Patno ME, Rapp R (1968) The survival of patients with inoperable lung cancer: a large randomized study of radiation therapy verses placebo. Radiology 90:688–697

    Article  Google Scholar 

  • Sandler HM, Curran WJ, Turrisi AT (1990) The influence of tumour size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 19:9–13. https://doi.org/10.1016/0360-3016(90)90127-6

    Article  Google Scholar 

  • Sanganalmath P, Lester JE, Bradshaw AG, Das T, Esler C, Roy AEF et al (2018) Continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC): 7 years’ experience from nine UK centres. Clin Oncol 30:144–150. https://doi.org/10.1016/j.clon.2017.12.019

    Article  Google Scholar 

  • Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M (1999) Continuous, hyper-fractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 52:137–148. https://doi.org/10.1016/s0167-8140(99)00087-0

    Article  Google Scholar 

  • Saunders MI, Rojas A, Lyn BE, Wilson E, Phillips H (2002) Dose escalation with CHARTWEL (continuous hyper-fractionated accelerated radiotherapy week end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol 14:352–360. https://doi.org/10.1053/clon.2002.0121

    Article  Google Scholar 

  • Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst 87(3):198–205. https://doi.org/10.1093/jnci/87.3.198

    Article  Google Scholar 

  • Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524–530

    Article  Google Scholar 

  • Sibley GS, Maguire PD, Anscher MA, Light K, Antoine P, Marks LB (1999) High-dose accelerated radiotherapy for non-small cell lung cancer: 7360 cGy and beyond. Int J Radiat Biol Phys 45:241

    Article  Google Scholar 

  • Slotman BJ, Njo H, Karim A (1994) Curative radiotherapy for technically operable stage 1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 29:33–37. https://doi.org/10.1016/0360-3016(94)90223-2

    Article  Google Scholar 

  • Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L et al (2022) Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40(12):1301–1311

    Google Scholar 

  • Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K et al (2017) Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non–small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol 35:2885–2892

    Article  Google Scholar 

  • Suhail A, Crocker CE, Das B, Payne JI, Manos D (2019) Initial presentation of lung cancer in the emergency department: a descriptive analysis. CMAJ Open 7(1):E117–E123. https://doi.org/10.9778/cmajo.2018006

    Article  Google Scholar 

  • Talton BM, Constable WC, Kersh CR (1990) Curative radiotherapy in non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 19:15–21. https://doi.org/10.1016/0360-3016(90)90128-7

    Article  Google Scholar 

  • Thirion P, Holmberg O, Collins CD, O’Shea C, Moriarty M, Pomeroy M et al (2004) Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 71:163–166. https://doi.org/10.1016/j.radonc.2003.09.006

    Article  Google Scholar 

  • Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop WJ (2001) Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 49:973–985

    Article  Google Scholar 

  • UK SABR Consortium (2019) Stereotactic ablative body radiation therapy (SABR): a resource. v6.1. https://www.sabr.org.uk/wp-content/uploads/2019/04/SABRconsortium-guidelines-2019-v6.1.0.pdf

  • van Baardwijk A, Wanders S, Boersma L, Borger J, Oellers M, Dingemans AMC et al (2010) Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 28(8):1380–1386

    Article  Google Scholar 

  • van Baardwijk A, Reymen B, Wanders S, Borger J, Ollers M, Dingemans AM et al (2012) Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III nonsmall cell lung cancer. Eur J Cancer 48(15):2339–2346

    Article  Google Scholar 

  • Westover KD, Loo BW Jr, Gerber DE, Iyengar P, Choy H, Diehn M et al (2015) Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial. Int J Radiat Oncol Biol Phys 93:72–81. https://doi.org/10.1016/j.ijrobp.2015.05.004

    Article  Google Scholar 

  • Wisnivesky JP, Bonomi M, Henschke C (2005) Radiation therapy for the treatment of stage I–II non-small cell lung cancer. Chest 128:1461–1467

    Article  Google Scholar 

  • Withers HR, Taylor JMG, Maciejewski B (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131–146

    Article  Google Scholar 

  • Wurschmidt F, Bunemann H, Bunemann C, Beck-Bornholdt HP, Heilmann HP et al (1994) Inoperable non-small cell lung cancer: a retrospective analysis of 427 patients treated with high dose radiotherapy. Int J Radiat Oncol Biol Phys 28:583–588. https://doi.org/10.1016/0360-3016(94)90182-1

    Article  Google Scholar 

  • Zehentmayr F, Grambozov B, Kaiser J, Fastner G, Sedlmayer F (2020) Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: a systematic review. Thorac Cancer 11:1375–1385. https://doi.org/10.1111/1759-7714.13451

    Article  Google Scholar 

  • Zeng K, Poon I, Ung Y, Zhang L, Cheung P (2018) Accelerated hypofractionated radiation therapy for centrally located lung tumors not suitable for stereotactic body radiation therapy (SBRT) or concurrent chemoradiotherapy (CRT). Int J Radiat Oncol Biol Phys 102:e719–ee20

    Article  Google Scholar 

  • Zhang HX, Yin WB, Zhang LJ, Yang ZY, Zhang ZX, Wang M et al (1989) Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol 14:89–94. https://doi.org/10.1016/0167-8140(89)90052-2

    Article  Google Scholar 

Download references

Acknowledgments

The review and comments on the manuscript by Dr. Patricia Fisher are greatly appreciated.

Author information

Authors and Affiliations

  1. Weston Park Hospital, Sheffield, UK

    Tathagata Das & Matthew Hatton

Authors
  1. Tathagata Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Hatton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Hatton .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Das, T., Hatton, M. (2023). Early Non-small Cell Lung Cancer: The Place of Radical Non-SABR Radiation Therapy. In: Jeremić, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2022_317

Download citation

  • DOI: https://doi.org/10.1007/174_2022_317

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-34846-4

  • Online ISBN: 978-3-031-34847-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation